1. The IRIS initiative is designed to assess any concomitant changes in the incidence of invasive disease caused by *S. pneumoniae* (pneumococcus), *H. influenzae* and *N. meningitidis* (meningococcus) during the COVID-19 pandemic.

2. Routine laboratory-confirmed invasive disease infection data for these three organisms from national reference labs in countries worldwide will be collected and analysed.

3. IRIS databases have been set up as private projects in the respective *S. pneumoniae*, *H. influenzae* and *Neisseria* PubMLST databases ([https://pubmlst.org/iris/](https://pubmlst.org/iris/)).

4. Data will be private and accessible only to participating laboratories.

5. Funding for the IRIS database is provided by the Wellcome Trust, which supports the PubMLST databases and infrastructure via a grant held by Prof Martin Maiden, Prof Angela Brueggemann and Dr Keith Jolley at the University of Oxford.

6. The persons responsible for the site (hereafter the Management Team) are as follows:
   - The oversight committee: Prof Angela Brueggemann (Oxford), Dr Mark van der Linden (Germany), Prof Martin Maiden (Oxford), Dr Keith Jolley (Oxford) and Dr Melissa Jansen van Rensburg (Oxford).
   - Website and database manager: Dr Keith Jolley (hereafter, the webmaster)
   - The above persons will not have any special privileges with regard to the analysis or publication of data compared to other users.

7. The laboratory submitting data to IRIS remains the owner of these data. To use unpublished data for publication purposes (e.g. conference presentations, internet presentations or journal publications), users of the database must obtain permission from the owner. The IRIS website must be acknowledged in all publications.

8. The preferred format of the acknowledgement is: ‘This publication made use of the Invasive Respiratory Infections Surveillance (IRIS) website ([https://pubmlst.org/iris/](https://pubmlst.org/iris/)). The development of this site has been funded by the Wellcome Trust.’

9. Data from other users of the database may not be provided to a third party without permission of the owner of the data.

10. As stated in (2), the Management Team will not have special privileges to analyse unpublished data for research purposes without the prior consent of the data owners; however, the Management Team reserves the right to provide 'current status' information on the website or in review articles including broad breakdowns by, for example, serogroup and country.

11. Participants and data submission
   - No patient information is recorded.
   - Multiple user accounts can be associated with an individual laboratory. Submissions can be made by any of these users and view access will be provided to all associated accounts.
   - Participants will be able to view data from the whole database. These data are only available to participants.
   - Even minimal isolate information may be valuable, so if only a serogroup assignment or non-culture diagnosis is available, please still submit.
   - Data fields will largely be the same as the current PubMLST database fields for each organism (submission templates found here: [https://pubmlst.org/iris/](https://pubmlst.org/iris/)).
   - Minimal data will be acceptable for submission, and the database entries can be updated with additional metadata and/or whole genome sequence data later if necessary.